Boston Scientific director buys 1,182 BSX shares

Boston Scientific Corp director David C. Habiger reported open-market purchases of Common Stock on two days in August 2026.

Accepted by SEC EDGAR 08/05/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Boston Scientific Corp director David C. Habiger reported open-market purchases of Common Stock on two days in August 2026. He bought 1,042 shares on August 3 at a weighted average price of $48.0655 per share and 140 shares on August 4 at a weighted average price of $48.5879 per share. Each trade was executed through multiple transactions within stated price ranges, with detailed per-trade pricing available on request.

Insider Trade Summary

Net Buyer: 1,182 shares

Net Buy 2 txns

Insider Habiger David C

Role Director

Bought 1,182 shs ($57K)

Increase in Position 8.5%

Type	Security	Shares	Price	Value
Purchase	Common Stock F2	140	$48.5879	$7K
Purchase	Common Stock F1	1,042	$48.0655	$50K

Holdings After Transaction: Common Stock — 15,060 shares (Direct)

Holdings Before and After: Common Stock, 13,878 to 15,060 shares (Direct)

Other Insiders: 2 other insiders reported open-market purchases of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $48.055 to $48.070, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
2. F2. Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $48.54 to $48.60, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Key Figures

Shares purchased 2026-08-03: 1,042 shares Shares purchased 2026-08-04: 140 shares Net shares purchased: 1,182 shares +2 more

5 metrics

Shares purchased 2026-08-03 1,042 shares Common Stock bought in open-market transactions at weighted average $48.0655 per share

Shares purchased 2026-08-04 140 shares Common Stock bought in open-market transactions at weighted average $48.5879 per share

Net shares purchased 1,182 shares Total Boston Scientific Common Stock purchased across both reported transactions

Price range 2026-08-03 $48.055 to $48.070 per share Range of prices for the 1,042-share purchase; weighted average $48.0655

Price range 2026-08-04 $48.54 to $48.60 per share Range of prices for the 140-share purchase; weighted average $48.5879

Key Terms

weighted average purchase price, multiple transactions, open market or private transaction

3 terms

weighted average purchase price financial

"Represents the weighted average purchase price for the shares purchased"

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

multiple transactions financial

"These shares were purchased in multiple transactions at prices ranging"

open market or private transaction financial

"Transaction code P described as Purchase in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who bought BSX shares in this Form 4 filing and in what role?

Director David C. Habiger of Boston Scientific Corp (BSX) reported buying Common Stock. He is identified as a director, with no officer or 10% owner status indicated in the filing.

How many BSX shares did David C. Habiger purchase in this Form 4?

David C. Habiger purchased a total of 1,182 shares of Boston Scientific Common Stock, comprising 1,042 shares on August 3, 2026 and 140 shares on August 4, 2026.

At what prices were the BSX shares bought in this Form 4?

The reported weighted average prices were $48.0655 per share for 1,042 shares on August 3, 2026 and $48.5879 per share for 140 shares on August 4, 2026, each reflecting multiple executions within disclosed price ranges.

What were the price ranges for the BSX purchases reported by David C. Habiger?

For the 1,042-share purchase on August 3, 2026, trades occurred between $48.055 and $48.070 per share. For the 140-share purchase on August 4, 2026, trades occurred between $48.54 and $48.60 per share.

Were the BSX insider purchases made in open-market transactions?

Yes. Both transactions are coded "P" with the description "Purchase in open market or private transaction", indicating the shares were acquired through market or similar purchase activity, rather than option exercises or gifts.

Does the BSX Form 4 indicate a Rule 10b5-1 trading plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not affirmed (set to false), and the footnotes describe only weighted average pricing and multiple executions, without referencing any trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Habiger David C

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MASSACHUSETTS 01752-1234

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		P		1,042	A	$48.0655(1)	14,920	D
Common Stock	08/04/2026		P		140	A	$48.5879(2)	15,060	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $48.055 to $48.070, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

2. Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $48.54 to $48.60, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

	/s/ Susan Thompson, Attorney-in-Fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)